TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Antengene Corporation Limited ( (HK:6996) ) has shared an update.
Antengene Corporation Limited announced its interim results for the first half of 2025, reporting a decrease in revenue to RMB53.2 million compared to the same period in 2024. Despite the revenue drop, the company saw a significant reduction in its losses, attributed to decreased research and development, selling, distribution, and administrative expenses. The inclusion of XPOVIO® in the 2023 NRDL initially boosted market growth, but demand has since stabilized. The company’s strategic cost management has resulted in a 52.2% reduction in adjusted losses, signaling improved financial health and operational efficiency.
The most recent analyst rating on (HK:6996) stock is a Hold with a HK$2.99 price target. To see the full list of analyst forecasts on Antengene Corporation Limited stock, see the HK:6996 Stock Forecast page.
More about Antengene Corporation Limited
Antengene Corporation Limited is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative therapeutics for oncology and other life-threatening diseases. The company is listed on the Hong Kong Stock Exchange under the stock code 6996.
Average Trading Volume: 6,108,365
Technical Sentiment Signal: Buy
Current Market Cap: HK$4.49B
For a thorough assessment of 6996 stock, go to TipRanks’ Stock Analysis page.